1. Home
  2. RAVE vs SKYE Comparison

RAVE vs SKYE Comparison

Compare RAVE & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rave Restaurant Group Inc.

RAVE

Rave Restaurant Group Inc.

HOLD

Current Price

$2.97

Market Cap

45.8M

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.75

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAVE
SKYE
Founded
1958
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.8M
44.9M
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
RAVE
SKYE
Price
$2.97
$0.75
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.75
AVG Volume (30 Days)
25.6K
259.0K
Earning Date
05-25-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
11.76
86.41
EPS
0.09
N/A
Revenue
$15,120,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$33.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.01
$0.68
52 Week High
$3.75
$5.75

Technical Indicators

Market Signals
Indicator
RAVE
SKYE
Relative Strength Index (RSI) 38.54 40.10
Support Level $2.73 $0.68
Resistance Level $3.21 $1.15
Average True Range (ATR) 0.17 0.06
MACD -0.04 0.01
Stochastic Oscillator 11.27 43.87

Price Performance

Historical Comparison
RAVE
SKYE

About RAVE Rave Restaurant Group Inc.

Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: